Esperion Announces Proposed Public Offering of Common Stock

Core Viewpoint - Esperion Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters [1][2] Company Overview - Esperion is a commercial stage biopharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C) [1][6] - The company has FDA approval for its oral medications aimed at patients at risk for cardiovascular disease, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [6] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [6][7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the SEC on April 18, 2025, and declared effective on April 29, 2025 [3] - The offering will be conducted through a written prospectus and a preliminary prospectus supplement will be filed with the SEC [3][5] - Joint book-running managers for the offering are Piper Sandler & Co. and Cantor Fitzgerald & Co. [2][4]